The cytochrome P450 superfamily of genes are well understood for their role in drug metabolism, with *CYP2D6* being the most extensively studied [@R1]--[@R4]. In clinical practice, *CYP2D6* has been referenced in the FDA approved labeling of over 40 different drugs citing issues of safety and/or efficacy in individuals with an altered metabolizer status ([*http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm*](http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm)). In addition, *CYP2D6* has been the focus of three separate professional guidelines for the utilization of codeine, tricyclic antidepressants, and selective serotonin reuptake inhibitors making it arguably one of the most valuable pharmacogenetic tools in guiding meaningful drug selection [@R5]--[@R7]. Although many *CYP2D6* variants have been identified that contribute to variability in enzymatic function, the gene is also known to have stably inherited gene deletion and duplication events [@R1]--[@R4],[@R8]. A deletion of *CYP2D6* is referred to in the literature as *CYP2D6\*5* and, when in a compound heterozygous state with another loss-of-function allele (e.g. *CYP2D6\*4*), has been shown to result in a poor metabolizer (PM) phenotype. *CYP2D6* gene duplication events are given the nomenclature of *CYP2D6\*xN*, with '*N*' signifying the presence of two or more copies of the gene on the same chromosome, often giving rise to an ultrarapid metabolizer (UM) phenotype ([*http://www.cypalleles.ki.se/cyp2d6.htm*](http://www.cypalleles.ki.se/cyp2d6.htm)) [@R7]. These PM and UM phenotypes are used as the basis for translating complex genotype information into clinically actionable results for pharmacologists and physicians. The prevalence of *CYP2D6* copy number variation (CNV) has been reported in the literature previously, but often with modest sample sizes or as a meta-analysis combining the data from several dipartite studies [@R7]. In this report, we provide *CYP2D6* CNV data on the single most comprehensive US population data set reported to date. The cohort consisted of 31 563 male (40.5%) and female (59.5%) patients with an average age of 61.2±20.7 years (±1 SD), referred for pharmacogenetic testing by an attending physician. *CYP2D6* copy number results were generated using gDNA isolated from buccal epithelial cells using QiaSymphony DNA extraction chemistry (cat. no. 937255; Qiagen, Germantown, Maryland, USA) and a commercially available copy number TaqMan assay for *CYP2D6* CNV determination targeting Exon 9 (cat. no. 4400291; Thermo Scientific, Waltham, Massachusetts, USA) with an RNase P internal reference TaqMan assay (cat. no. 4403328; Thermo Scientific) coamplified in a duplex PCR reaction using the ViiA 7 Real Time PCR System (Thermo Scientific). Although this biplexed TaqMan assay combination is commonly used in clinical practice, it should be noted that in rare instances, an assay targeting Exon 9 could produce a three copy result from a two copy sample when a sample has a nonfunctional *CYP2D7/2D6* hybrid gene structure (which includes the *CYP2D6* Exon 9 region) in tandem with a functional copy of a *CYP2D6* (e.g. *\*76+\*1*, *\*77+\*2*, and *\*78+\*2*). Samples were run in quadruplicates and a custom algorithm used to average replicate data and assign a predicted copy number based on sample ΔΔ*C*~t~ values calibrated against a *CYP2D6* two copy control [@R2]. On the basis of these calculations, samples were classified as containing zero, one, two, or three or more copies of the *CYP2D6* gene (Fig. [1](#F1){ref-type="fig"}a). The overall distribution of CNVs demonstrated that only 87.4% (27 589) of the patients possessed two copies of the *CYP2D6* gene, whereas 12.6% (*n*=3974) of the patients were classified as having zero, one, or three or more copies of the gene. Approximately 7.2% (2288) of the population had only one copy of *CYP2D6* and 5.2% (1643) of the population had three or more copies. Roughly two-thirds of the samples (*n*=21 472) in the cohort included data on self-reported ethnicity with selections including; African American, Asian, Caucasians, Hispanic, or other. The distribution of ethnicity among the self-reported samples closely mirrors the results of the 2010 US census ([*http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf*](http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf)), suggesting the *CYP2D6* CNV frequency data obtained in this study is reflective of the relative diversity of the US population (Fig. [1](#F1){ref-type="fig"}b).

![Distribution of samples containing zero, one, two, and three or more copies of the *CYP2D6* gene. (a) Percentages of samples containing zero, one, two, and three or more copies of the *CYP2D6* gene throughout the entire sample set (*n*=31 563), actual sample numbers in parentheses. (b) Percentages of self-reported ethnicity in the US 2010 Census as compared with the selected sample set, Caucasians (light grey), African Americans (diagonal lines), and Asians (dots). (c) Percentages of samples containing one, two, and three or more copies of the *CYP2D6* gene stratified based on self-reported ethnicity (*n*=21 472), actual sample numbers in parentheses, Caucasians (light grey), African Americans (diagonal lines), Asians (dots), and Hispanics (diamonds).](fpc-26-96-g001){#F1}

For the sample set in which ethnicity was provided, data was stratified accordingly and the percentages of *CYP2D6* one, two, and three or more copy patients were determined. Although the frequency of *CYP2D6* 'two copy' patients was indistinguishable among Caucasians, Asians, and Hispanics; patients of African American ethnicity demonstrated statistically significant differences when compared with other ethnicities (*Z*-test for two proportions, *P*\<0.01). Consistent with this observation, the percentage of one copy samples was 1.5- to 2.1-fold higher and the percentage of three or more copy samples was 1.4- to 3.4-fold higher in African Americans, as compared with other ethnicities (Fig. [1](#F1){ref-type="fig"}c). In addition, we identified 43 patients in our set of 31 563 who had no detectable copies of *CYP2D6* (i.e. *CYP2D6\*5* homozygotes or 'zero copy' samples), translating to ∼0.14% of the US population. Although stratification by ethnicity resulted in single sample representation for Asians and Hispanics, African American patients demonstrated the highest probability of being *CYP2D6\*5* homozygotes at 0.33% (*n*=9/2694 or ∼1/300), followed next by Caucasians at 0.11% (17/16 026 or ∼1/940) (Table [1](#T1){ref-type="table"}). Of particular note, 38 of the 43 patients identified as having 'zero copies' of the gene had a list of the medications the patient was currently taking. For those 38 patients, 68% (*n*=26) were taking at least one medication metabolized by CYP2D6.

###### 

Frequency of CYP2D6\*5 homozygotes
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We believe this report represents the single largest evaluation of *CYP2D6* CNV distribution in a clinically relevant US population. Recently, a comprehensive meta-analysis of *CYP2D6* CNV frequencies was published in 2015 CPIC guidelines [@R7]. Although the maximum and minimum frequencies reported in these guidelines were broad, the average allele frequencies calculated in these guidelines are generally supported by our findings (Table [2](#T2){ref-type="table"}). However, it is of particular interest that the *CYP2D6\*5* allele frequencies for patients of African American ethnicity appear higher (+0.93%) in this study as compared with the percentage calculated from the CPIC meta-analysis (Table [2](#T2){ref-type="table"}). This could have resulted from using a population that had been referred for pharmacogenetic testing or this may simply be a reflection of a large singular data set, obtained under rigorous clinical conditions, revealing a more statistically meaningful set of outcomes. Regardless, the relevance of this data set is in looking at a significant cross-section of the US population deemed eligible for pharmacogenetic testing by physicians and understanding the relative impact of *CYP2D6* CNV determination.

###### 

CYP2D6 CNV allelic frequencies by ethnicity
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Pharmacogenetics-based therapies reserve the strongest recommendations for therapeutic intervention for individuals classified as PMs and UMs [@R5]--[@R7]. The majority of *CYP2D6* PM phenotypes arise from diplotypes of four nonfunctional alleles; *CYP2D6\*3*, *CYP2D6\*4*, *CYP2D6\*5* and *CYP2D6\*6*. Our results establish that the allelic frequency of *CYP2D6\*5* in the US population is ∼3.76% (assuming Hardy--Weinberg equilibrium) making it the second most frequent 'nonfunctional' allele behind *CYP2D6\*4* [@R7]. Although not all patients containing three or more copies of *CYP2D6* are UMs, UM phenotypes arise almost entirely from the presence of more than two functional copies of the *CYP2D6* gene (*CYP2D6\*xN* alleles). In our data set, we had corresponding *CYP2D6* diplotype information for 1448 of the ≥3 copy samples identified. On the basis of the translational tables provided in the study by Hicks and Colleagues [@R7], ∼52% (750/1448) of the samples could be clearly classified as UMs as only functional variants of *CYP2D6* were detected (e.g. *\*1/\*1*, *\*1/\*2*, and *\*2/\*2*). An additional ∼15% (220/1448) were possible UMs based on the presence of a reduced function allele in combination with a functional allele (e.g. *\*1/\*41*, *\*2/\*41*). This would indicate that the prevalence of functional UM phenotypes in the US population should be estimated between 2.71 and 3.49% (5.21%×0.52 to 5.21%×0.67). It has been recently noted that 'scientists have largely overlooked the influence of gene duplications or deletions - on drug response' and that some laboratory-developed tests identify only the single nucleotide polymorphisms of interest and do not interrogate for *CYP2D6* CNVs [@R9]. We believe that the combined prevalence of *CYP2D6* CNVs, along with their relative contributions to deleterious PM and UM phenotypes, underscores the importance of determining *CYP2D6* CNV in the clinical practice of pharmacogenomics.
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